BOLD-100 is under clinical development by Bold Therapeutics and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase II drugs for Gastroesophageal (GE) Junction Carcinomas have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BOLD-100’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BOLD-100 overview

BOLD-100 (IT-139, NKP-1339) is under development for the treatment of solid tumors including pancreatic cancer, gastroesophageal (GE) junction carcinomas, gastric cancer, lung cancer, colon cancer, gastrointestinal tumor, treatment-resistant metastatic colorectal cancer (mCRC), bile duct cancer, pancreatic cancer, pancreatic ductal adenocarcinoma,triple-negative breast cancer, sarcomas, bladder cancer, multiple myeloma, esophageal squamous cell carcinoma (ESCC) and coronavirus disease (COVID-19). It is sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]. The drug candidate is administered through intravenous route. It targets GRP78. It was also under development for the treatment of neuroendocrine tumors, non-small cell lung cancer, breast cancer, esophageal cancer, osteosarcoma, metastatic melanoma and liver cancer. It acts as PD-1 inhibitor.

Bold Therapeutics overview

Bold Therapeutics is a clinical-stage biotechnology company developing cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers in combination with existing anti-cancer therapies. The company is headquartered in Vancouver, British Columbia.

For a complete picture of BOLD-100’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.